Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2024-12-20 00:00:00 ET · period of report 2024-12-19 · accession 0001601830-24-000249 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-20 | 2024-12-19 | RXRX | Taylor Ben R | CFO | A - Grant | $0.00 | +370.3K | 844.2K | +78% | $0 |
| D | 2024-12-20 | 2024-12-19 | RXRX | Taylor Ben R | CFO | A - Grant | $0.00 | +740.7K | 740.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-12-19 | A | A | 370,343 | $0.00 | 844,210 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-12-19 | A | A | 740,686 | $0.00 | 740,686 | D | $6.09 · — to 2034-12-18 | 740,686 Class A Common Stock | (F2) 1/48th of the shares subject to the award vests and become exercisable on January 2, 2025, and each month thereafter, subject to Mr. Taylor's continued service through each vesting date. |